Drug intelligence / Profile preview

Qilongdingchuanpian

Development stage: Unknown
Lead developer: Yiling Pharmaceutical
Administration: Oral

Overview

Qilongdingchuanpian is a traditional Chinese medicine (TCM) developed by Shijiazhuang Yiling Pharmaceutical for the treatment of stable chronic obstructive pulmonary disease (COPD). It is formulated as an oral tablet and is designed to address the TCM patterns of heart–lung qi deficiency and phlegm–blood stasis. The drug is currently undergoing Phase II clinical evaluation (e.g., trial CTR20262866) to determine its efficacy, safety, and optimal dosing in adult patients with stable COPD.

Other names: 芪龙定喘片

Beyond the preview

Go deeper on Qilongdingchuanpian.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qilongdingchuanpian.

Explore the full profile